Answer
Comirnaty KP.2 (cemivameran) uses lipid nanoparticles to deliver non-replicating mRNA into host cells, directing temporary production of SARS-CoV-2 spike antigen and eliciting neutralising antibody and cellular immune responses that may contribute to protection against COVID-19.
Sources for this answer
- Comirnaty KP.2 30 microgram/dose dispersion for injection in pre-filled syringeBioNTech - Pfizer · emc · SmPC §5.1 Pharmacodynamic properties · Version 6Document updated
Sources checked